ICU Medical, Inc. $ICUI Holdings Decreased by Nitorum Capital L.P.

Key Points

• Nitorum Capital L.P. reduced its stake in ICU Medical by 12.6%, selling 25,144 shares and holding 174,901 shares, which now makes up approximately 3.4% of its portfolio.
• ICU Medical's most recent earnings report showed that earnings per share were $2.10, exceeding analyst expectations of $1.44, despite an 8% decline in quarterly revenue year-over-year.
• Wall Street analysts have mixed ratings on ICU Medical, with current consensus showing an average rating of "Buy" and a target price of $179.00.

Nitorum Capital L.P. decreased its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 12.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 174,901 shares of the medical instruments supplier's stock after selling 25,144 shares during the period. ICU Medical comprises approximately 3.4% of Nitorum Capital L.P.'s portfolio, making the stock its 11th biggest holding. Nitorum Capital L.P. owned 0.71% of ICU Medical worth $24,287,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ICUI. Xponance Inc. boosted its stake in ICU Medical by 5.3% in the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier's stock worth $238,000 after buying an additional 86 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of ICU Medical by 23.0% in the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock valued at $111,000 after purchasing an additional 150 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of ICU Medical by 27.2% in the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 153 shares in the last quarter. Vise Technologies Inc. lifted its stake in shares of ICU Medical by 7.1% in the 4th quarter. Vise Technologies Inc. now owns 2,649 shares of the medical instruments supplier's stock valued at $411,000 after purchasing an additional 176 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of ICU Medical by 2.5% in the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier's stock valued at $1,297,000 after purchasing an additional 229 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain acquired 21,929 shares of the company's stock in a transaction on Thursday, August 14th. The shares were bought at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the acquisition, the chief executive officer directly owned 130,149 shares of the company's stock, valued at $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Greenberg acquired 1,200 shares of the company's stock in a transaction on Wednesday, August 27th. The shares were acquired at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the acquisition, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is owned by insiders.

ICU Medical Stock Up 2.0%

Shares of NASDAQ:ICUI traded up $2.65 during mid-day trading on Wednesday, hitting $133.22. 128,869 shares of the company traded hands, compared to its average volume of 266,332. The firm has a market cap of $3.29 billion, a P/E ratio of -87.64 and a beta of 0.86. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. ICU Medical, Inc. has a 52-week low of $107.00 and a 52-week high of $196.26. The firm's 50 day simple moving average is $126.39 and its 200 day simple moving average is $134.20.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The business had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. During the same period last year, the business posted $1.56 EPS. The company's revenue was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, equities analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ICUI shares. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a research note on Friday, September 5th. Piper Sandler lifted their price objective on ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, Raymond James Financial reduced their price objective on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $181.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.